A little-known force is now controlling the S&P's price action — and most traders have no idea it exists. A former VP of a trillion-dollar firm has spent years cracking it, and the results speak for themselves: a 79.4% win rate with same-day returns like 176% and 75.4% — up or down market, it doesn't matter.
This isn't mainstream. It won't be on CNBC. But right now, you can get the full breakdown — including how to use this force to target double- and triple-digit moves today. Don't sit this one out.
Get the Free Breakdown NowWe develop tools and strategies to the best of our ability, but we can't guarantee the future. In LIVE trading alerts in real time from 08/23/24 to 3/28/26, the strategy is 54-14, with an overall win rate of 79.4% and an average return (winners and losers included) of 59.3%, with an average winner of 86.8% over a 1-day hold time. Trade at your own risk. By clicking the link above you agree to periodic updates from The TradingPub and its partners. Privacy Policy.
Friday, July 17, 2026 | Never Lose Sleep About What You Missed.
Image via Fox News
Shooting near Aurora ICE facility leaves one injured; suspect detained
A shooting near an ICE detention facility in Aurora, Colorado, left a woman with injuries that authorities said were not life-threatening. Police detained one person for questioning as they worked to sort out what happened and whether the facility or its operations were connected to the incident.
The episode lands amid a broader national spike in tension around immigration enforcement, where protests, counter-protests, and heightened security postures have become more common near federal sites. For locals, the immediate questions are basic but important: who was targeted, what prompted the gunfire, and whether there’s any continuing risk to nearby neighborhoods.
Source: Fox News
Read the full story at Fox News →
Image via Axios
Epstein survivors say Blanche meeting felt like a box-check
Multiple survivors of Jeffrey Epstein’s abuse criticized a long-awaited meeting with attorney general nominee Todd Blanche, describing it as dismissive and "demoralizing." Their accounts suggest they expected a substantive discussion about accountability and next steps, but left feeling heard in form rather than in substance.
The reaction matters because the Epstein cases sit at the intersection of public trust and prosecutorial discretion: survivors want transparency on what was done, what wasn’t, and why. Politically, Blanche now faces a credibility test early in the confirmation spotlight, where perceived indifference can become a defining narrative faster than any policy memo.
Source: Axios
Read the full story at Axios →
Image via The Hill
Markey calls for Trump impeachment over new election claims
Sen. Ed Markey (D-Mass.) called on Congress to impeach President Trump after Trump made fresh election-related claims during a primetime address, according to The Hill. Markey framed the remarks as a threat to democratic stability and argued they warranted impeachment proceedings.
Impeachment talk is a familiar Washington reflex, but it still has consequences: it hardens partisan lines, shifts media oxygen away from legislation, and forces leadership to decide whether to indulge a base demand or treat it as political theater. Watch whether other Senate Democrats echo Markey, and whether House leaders signal any appetite for escalation or shut it down quickly.
Source: The Hill
Read the full story at The Hill →
Image via Politico
Platner’s meltdown is now a career problem for the consultants who built him
The fallout from Platner’s early stumbles is widening beyond the candidate himself, with scrutiny now aimed at the young, out-of-state consultants and operatives who recruited and shaped his effort, Politico reports. The piece describes a chain of misjudgments, including turning down an offer for deeper vetting, that now looks like avoidable self-sabotage.
In the consultant economy, reputation is currency, and "we didn’t know" is rarely an acceptable defense when campaigns detonate on basic diligence. The practical implication is simple: donors and committees will remember who signed off, not who complained privately, and the next hiring cycle will reflect that.
Source: Politico
Read the full story at Politico →
Image via Washington Examiner
America’s biotech edge vs. China: the plan is coming, but politics could kneecap it
A Washington Examiner opinion column argues the U.S. can regain momentum in the biotech race with China through a new push described as "Operation Trailblazer," focused on clinical research capacity, speed, and national-security resilience. The author warns that policy missteps and internal resistance could blunt the effort, specifically pointing to concerns about RFK Jr.’s influence as a potential drag on biomedical innovation.
The underlying issue is real even if the framing is partisan: biotech leadership is now a strategic asset, not just a health-care storyline, touching supply chains, biosecurity, and economic competitiveness. What to watch is whether any initiative translates into durable reforms like faster trial approval pathways, better data infrastructure, and clearer rules that attract private capital instead of scaring it off.
Source: Washington Examiner
Read the full story at Washington Examiner →
That’s the day. Five minutes, fully caught up. See you next issue.
— Daily Recap Editorial